Drug
Retifanlimab
Retifanlimab: highest development phase Phase 1/2, developed by Incyte. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| Retifanlimab NCT04577014 | Phase 1/2 | Soft Tissue Sarcoma |
| Retifanlimab NCT03589651 | Phase 1 | Unresectable or Metastatic Solid Tumors |
Latest
No recent events.
Follow Retifanlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.